– GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing – – SOD1 ALS gene therapy program on track for development candidate selection by end of year – – Conference call at 4:30 p.m. ET today – LEXINGTON, Mass. , Nov.
Categories
Recent Posts
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
- Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
- Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)